Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alx Oncology Holdings (ALXO) Non-Current Debt (2019 - 2023)

Alx Oncology Holdings' Non-Current Debt history spans 5 years, with the latest figure at $9.6 million for Q3 2023.

  • For Q3 2023, Non-Current Debt rose 283.0% year-over-year to $9.6 million; the TTM value through Sep 2023 reached $9.6 million, up 283.0%, while the annual FY2022 figure was $9.4 million, 570.64% up from the prior year.
  • Non-Current Debt for Q3 2023 was $9.6 million at Alx Oncology Holdings, up from $9.5 million in the prior quarter.
  • Across five years, Non-Current Debt topped out at $9.6 million in Q3 2023 and bottomed at $1.4 million in Q4 2021.
  • The 5-year median for Non-Current Debt is $4.7 million (2019), against an average of $5.7 million.
  • The largest annual shift saw Non-Current Debt surged 570.64% in 2022 before it skyrocketed 280.48% in 2023.
  • A 5-year view of Non-Current Debt shows it stood at $5.4 million in 2019, then tumbled by 41.17% to $3.2 million in 2020, then tumbled by 56.1% to $1.4 million in 2021, then soared by 570.64% to $9.4 million in 2022, then rose by 1.98% to $9.6 million in 2023.
  • Per Business Quant, the three most recent readings for ALXO's Non-Current Debt are $9.6 million (Q3 2023), $9.5 million (Q2 2023), and $9.4 million (Q1 2023).